Coccidioidal meningitis: clinical presentation and management in the fluconazole era.
Despite the advent of new antifungal agents, coccidioidal meningitis (CM) remains a difficult-to-treat condition with significant morbidity and mortality. In this study we directly compare the clinical presentation and management of patients with Coccidioides immitis meningitis in the azole era (after 1980) to that of a cohort of patients from the pre-azole era. We reviewed 30 CM cases seen at 3 Los Angeles hospitals between the years 1993 to 2008 ("2008 cohort") and compared them to 31 patients ("1980 cohort") described by Bouza et al in a previous study. The demographics and clinical presentation of patients in the 2008 cohort were similar to those of the 1980 cohort except for a higher incidence of Hispanic patients (2008: 53% vs. 1980: 6%) and a greater percentage of patients with underlying, predisposing clinical conditions (2008: 66% vs. 1980: 32%). Ten patients in the 2008 cohort had human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), a condition not reported in the earlier study. Laboratory findings were similar between the 2 groups except for a lower incidence of peripheral leukocytosis and eosinophilia in the 2008 group.There were marked differences in drug treatment between the 2 eras. In the 2008 cohort, 29 patients received fluconazole therapy: 13 were treated with fluconazole monotherapy, and 16 received a combination of fluconazole and intravenous amphotericin B. Although almost all patients (29/31) in the 1980 cohort received intrathecal amphotericin B, only 3 patients in the 2008 study received amphotericin B via this route. With respect to complications of CM, a similar percentage of patients in each cohort developed complications such as stroke and hydrocephalus. The 2008 cohort (40%) had similar mortality compared to patients in the 1980 study (39%); survivors in both groups experienced significant impairment of activities of daily living. Although recommended as first-line therapy for CM, azole-based therapies are not curative and do not necessarily prevent complications associated with the disease.CM remains a serious illness with a high rate of morbidity and mortality. Immunocompromised individuals, especially those with HIV/AIDS, are at special risk for CM and represent a greater share of the overall population with this condition. Despite the clear advantages of azole treatment in CM, new therapeutic approaches are needed to provide definitive cure and to reduce the need for long-term suppressive therapy.
Mathisen
Glenn
G
From Cedars Sinai-UCLA Affilialted Multicampus Infectious Disease Program (GM, AS, JT, CW), Los Angeles; Cedars Sinai Medical Center, Los Angeles; Olive View-UCLA Medical Center (GM, JT, CW), Sylmar; VA West Los Angeles Medical Center, Los Angeles; Los Angeles County Department of Public Health (CW), Los Angeles; and Southern California Kaiser Permanente Medical Group (JT), Los Angeles, California.
Shelub
Aaron
A
Truong
Jonathan
J
Wigen
Christine
C
D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis / Q000188:drug therapy; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000453:epidemiology; D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D003045:Coccidioides / Q000302:isolation & purification*; D003047:Coccidioidomycosis / Q000134:cerebrospinal fluid / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use*; D006801:Humans; D006849:Hydrocephalus / Q000453:epidemiology; D008297:Male; D008581:Meningitis / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000382:microbiology*; D008875:Middle Aged; D013902:Radiography, Thoracic; D055815:Young Adult
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D000666:Amphotericin B; D015725:Fluconazole
Abbott KH, Cutler OI. Chronic coccidioidal meningitis: review of the literature and report of seven cases. Arch Pathol. 1936;21:320-330.
Ampel NM. Delayed-type hypersensitivity, in vitro T-cell responsiveness and risk of active coccidioidomycosis among HIV-infected patients living in the coccidioidal endemic area. Med Mycol. 1999;37:245-250.
Arsura EL, Johnson R, Penrose J, Stewart K, Kilgore W, Reddy CM, Bobba RK. Neuroimaging as a guide to predict outcomes for patients with coccidioidal meningitis. Clin Infect Dis. 2005;40:624-627.
Berry CD, Stevens DA, Hassid EI, Pappagianis D, Happs EL, Sahrakar K. A new method for the treatment of chronic fungal meningitis: continuous infusion into the cerebrospinal fluid for coccidioidal meningitis. Am J Med Sci. 2009;338:79-82.
Blair JE, Coakley B, Santelli AC, Hentz JG, Wengenack NL. Serologic testing for symptomatic coccidioidomycosis in immunocompetent and immunosuppressed hosts. Mycopathologia. 2006;162:317-324.
Blair JE. Coccidioidomycosis in liver transplantation. Liver Transpl. 2006;12:31-39.
Bouza E, Dreyer JS, Hewitt WL, Meyer RD. Coccidioidal meningitis. An analysis of thirty-one cases and review of the literature. Medicine (Baltimore). 1981;60:139-172.
Brockmeyer NH, Tillmann I, Mertins L, Barthel B, Goos M. Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. Eur J Med Res. 1997;2:377-383.
Caldwell JW, Arsura EL, Kilgore WB, Garcia AL, Reddy V, Johnson RH. Coccidioidomycosis in pregnancy during an epidemic in California. Obstet Gynecol. 2000;95:236-239.
Carmichael JK. Coccidioidomycosis in HIV-infected persons. Clin Infect Dis. 2006;42:1059.
Classen DC, Burke JP, Smith CB. Treatment of coccidioidal meningitis with fluconazole. J Infect Dis. 1988;158:903-904.
Clemons KV, Sobel RA, Williams PL, Pappagianis D, Stevens DA. Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits. Antimicrob Agents Chemother. 2002;46:2420-2426.
Cloud G, Dismukes WE. Ketoconazole treatment of coccidioidal meningitis. Ann N Y Acad Sci. 1988;544:488-496.
Cortez KJ, Walsh TJ, Bennett JE. Successful treatment of coccidioidal meningitis with voriconazole. Clin Infect Dis. 2003;36:1619-1622.
Courville CB, Abbott KH. Pathology of coccidioidal granuloma of the central nervous system and its envelopes. Bull Los Angeles Neurol Soc. 1938;3:27-e41.
Crum NF, Ballon-Landa G. Coccidioidomycosis in pregnancy: case report and review of the literature. Am J Med. 2006;119:993.e11-e17.
Dewsnup DH, Galgiani JN, Graybill JR, Diaz M, Rendon A, Cloud GA, Stevens DA. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med. 1996;124:305-310.
Einstein HE, Holeman CW, Sandidge LL, Holden DH. Coccidioidal meningitis. The use of amphotericin B in treatment. Calif Med. 1961;94:339-343.
Fish DG, Ampel NM, Galgiani JN, Dols CL, Kelly PC, Johnson CH, Pappagianis D, Edwards JE, Wasserman RB, Clark RJ, Antoniskis D, Larsen RA, Englender SJ, Petersen EA. Coccidioidomycosis during human immunodeficiency virus infection. A review of 77 patients. Medicine (Baltimore). 1990;69:384-391.
Galgiani JN, Catanzaro A, Cloud GA, Levine BE, Williams PL, Johnson RH, Rendon A, Mirels LF, Lutz JE, Holloway M, Galgiani JN. Fluconazole therapy for coccidioidal meningitis. The NIAID-Mycoses Study Group. Ann Intern Med. 1993;119:28-35.
Graybill JR, Sun SH, Ahrens J. Treatment of murine coccidioidal meningitis with fluconazole (UK 49,858). J Med Vet Mycol. 1986;24:113-119.
Hooper JE, Lu Q, Pepkowitz SH. Disseminated coccidioidomycosis in pregnancy. Arch Pathol Lab Med. 2007;131:652-655.
Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003;36:630-637.
Johnson RH, Einstein HE. Coccidioidal meningitis. Clin Infect Dis. 2006;42:103-107.
Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H; Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58(RR-4):1-207.
Kriesel JD, Sutton DA, Schulman S, Fothergill AW, Rinaldi MG. Persistent pulmonary infection with an azole-resistant Coccidioides species. Med Mycol. 2008;46:607-610.
Li RK, Ciblak MA, Nordoff N, Pasarell L, Warnock DW, McGinnis MR. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob Agents Chemother. 2000;44:1734-1736.
Masannat FY, Ampel NM. Coccidioidomycosis in patients with HIV-1 infection in the era of potent antiretroviral therapy. Clin Infect Dis. 2010;50:1-7.
McMahon JH, Grayson ML. Torsades de pointes in a patient receiving fluconazole for cerebral cryptococcosis. Am J Health Syst Pharm. 2008;65:619-623.
Mischel PS, Vinters HV. Coccidioidomycosis of the central nervous system: neuropathological and vasculopathic manifestations and clinical correlates. Clin Infect Dis. 1995;20:400-405.
Morris M. Coccidioides of the central nervous system. Cal West Med. 1924;22:483-485.
Ophuls W. Coccidioidal granulomas. J Am Med Assoc. 1905;14:1291.
Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201-211.
Peterson CM, Johnson SL, Kelly JV, Kelly PC. Coccidioidal meningitis and pregnancy: a case report. Obstet Gynecol. 1989;73:835-836.
Posadas A. Un nuevo caso de micosis fungoide con psorospermias. Circulo Medico Argentino. 1892;5:585-597.
Prabhu RM, Bonnell M, Currier BL, Orenstein R. Successful treatment of disseminated nonmeningeal coccidioidomycosis with voriconazole. Clin Infect Dis. 2004;39:e74-e77.
Proia LA, Tenorio AR. Successful use of voriconazole for treatment of Coccidioides meningitis. Antimicrob Agents Chemother. 2004;48:2341.
Pursley TJ, Blomquist IK, Abraham J, Andersen HF, Bartley JA. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis. 1996;22:336-340.
Rixford E, Gilchrist TC. Two cases of protozoan (coccidioidal) infection of the skin and other organs. Johns Hopkins Hosp Rep. 1896;1:209-269.
Romeo JH, Rice LB, McQuarrie IG. Hydrocephalus in coccidioidal meningitis: case report and review of the literature. Neurosurgery. 2000;47:773-777.
Santhana Krishnan SG, Cobbs RK. Reversible acute adrenal insufficiency caused by fluconazole in a critically ill patient. Postgrad Med J. 2006;82:e23.
Singh VR, Smith DK, Lawrence J, Kelly PC, Thomas AR, Spitz B, Sarosi GA. Coccidioidomycosis in patients infected with human immunodeficiency virus: review of 91 cases at a single institution. Clin Infect Dis. 1996;23:563-568.
Sorensen KN, Sobel RA, Clemons KV, Pappagianis D, Stevens DA, Williams PL. Comparison of fluconazole and itraconazole in a rabbit model of coccidioidal meningitis. Antimicrob Agents Chemother. 2000;44:1512-1517.
Spinello IM, Johnson RH, Baqi S. Coccidioidomycosis and pregnancy-a review. Ann N Y Acad Sci. 2007;1111:358-364.
Stevens DA, Shatsky SA. Intrathecal amphotericin in the management of coccidioidal meningitis. Semin Respir Infect. 2001;16:263-269.
Sung JP, Grendahl JG, Levine HB. Intravenous and intrathecal miconazole therapy for systemic mycoses. West J Med. 1977;126:5-13.
Tholakanahalli VN, Potti A, Hanley JF, Merliss AD. Fluconazole-induced torsade de pointes. Ann Pharmacother. 2001;35:432-434.
Tucker RM, Denning DW, Dupont B, Stevens DA. Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med. 1990;112:108-112.
Tucker RM, Galgiani JN, Denning DW, Hanson LH, Graybill JR, Sharkey K, Eckman MR, Salemi C, Libke R, Klein RA, et al. Treatment of coccidioidal meningitis with fluconazole. Rev Infect Dis. 1990;12(Suppl 3):S380-S389.
Vincent T, Galgiani JN, Huppert M, Salkin D. The natural history of coccidioidal meningitis: VA-Armed Forces cooperative studies, 1955-1958. Clin Infect Dis.. 1993;16:247-254.
Williams PL, Johnson R, Pappagianis D, Einstein H, Slager U, Koster FT, Eron JJ, Morrison J, Aguet J, River ME. Vasculitic and encephalitic complications associated with Coccidioides immitis infection of the central nervous system in humans: report of 10 cases and review. Clin Infect Dis. 1992;14:673-682.
Williams PL. Vasculitic complications associated with coccidioidal meningitis. Sem Resp Infect. 2001;16:270-279.
Winn WA. The use of amphotericin B in the treatment of coccidioidal disease. Am J Med. 1959;27:617.
Winston DJ, Kurtz TO, Fleischmann J, Morgan D, Batzdorf U, Stern WE. Successful treatment of spinal arachnoiditis due to coccidioidomycosis. Case report. J Neurosurg. 1983;59:328-331.